NAME : MS. SHRIYA R ICMR / NABL No.

: ADLCTN / MC-2117
PIN : AND21630146001 SAMPLE NO : 6321146114
AGE/GENDER : 15 Year(s)/Female COLLECTED ON : 04/01/2022 10:30 AM
REFERRED BY : Dr.KUMARAN HOSPITAL . BILLED ON : 04/01/2022 08:58 AM
CLIENT NAME : KUMARAN HOSPITAL REPORTED ON : 04/01/2022 02:42 PM

COVID-19 (SARS-CoV-2) QUALITATIVE RT-PCR

Methodology : Reverse Transcriptase Real Time Polymerase Chain Reaction
Type of Specimen : Nasopharyngeal & Oropharyngeal

Interpretation : NEGATIVE FOR COVID

Result
Gene Targets Result Ct Values
N Gene NEGATIVE -
ORF 1 AB NEGATIVE -

Ct Value range
High Positive : 10 to 18
Medium Positive : 19 to 27
Borderline Positive : 28 to 33
Borderline positive tests should be repeated after three days for confirmation. Borderline
positive results can happen during waxing or waning phase of the infection or in
symptomatic cases.
CONDITIONS OF REPORTING:
1. Some patients may have CT chest findings and negative RT-PCR for SARS-CoV2 in the
initial stages. If CT Chest is highly suggestive, repeat sample after 3 to 5 days is
suggested and patient may be managed accordingly in the interim period.
2. Detection of SARS-Cov2 is better from lower respiratory fluid followed by Nasopharynx
and oropharynx.
3. Detection of SARS-Cov2 is dependent on proper collection technique and VTM.SARS-Cov2
may notbe detected in the incubation period or during delayed nucleic acid conversion.
4. Host - Pathogen causes result in a sensitivity of 70 to 80% at symptom onset with higher
probability during the first 5 days of symptom onset.
5. SARS-Cov2 may be detected in asymptomatic or presymptomatic stages also.
6. Test results should not be the sole guiding criterion for treatment. The result must be
interpreted in specific epidemiological, clinical and CT Imaging contexts.

METHODOLOGY
Realtime RTPCR technology utilizes reverse transcriptase RT reaction to convert RNA into
complementary DNA, cDNA polymerase chain reaction PCR for the amplification of specific
target sequences and target-specific probes for the detection of the amplified DNA.

Page 1 / 2
NAME : MS. SHRIYA R ICMR / NABL No. : ADLCTN / MC-2117
PIN : AND21630146001 SAMPLE NO : 6321146114
AGE/GENDER : 15 Year(s)/Female COLLECTED ON : 04/01/2022 10:30 AM
REFERRED BY : Dr.KUMARAN HOSPITAL . BILLED ON : 04/01/2022 08:58 AM
CLIENT NAME : KUMARAN HOSPITAL REPORTED ON : 04/01/2022 02:42 PM

The probes are labelled with florescent reporter and quencher dyes. The assay includes
heterologousamplification system (internal control) to identify possible RT-PCR inhibition
and to confirm the integrity of the reagents of the kit. This methodology is used for the
qualitative detection and differentiation of lineage B-betacoronavirus (B-βov) and
severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific RNA in the clinical
sample.

PATHOGEN INFORMATION
SARS-Cov-2 is an enveloped positive strand RNA virus belonging the family Coronaviridae,
suborder Cornidovirineae, order Nidovirales and realm Riboviria as developed by the
Coronaviridae Study Group (CSG). The pathogen belongs to Genus Betacoronaviridae and
Species Severe acute respiratory syndrome-associated virus (2).

GENOME INFORMATION

Note:
1. NABL and ICMR approved lab for SARS-Cov2 Testing.
2. SARS-CoV-2 test done by ICMR/FDA/CE-IVD approved kits.
3. Test should be always clinically correlated.
4. Repeat the test with lower respiratory tract sample if necessary.
5. Please refer to current ICMR testing guidelines to refer patients for testing.

REFERENCES:
1. https://main.icmr.nic.in/content/covid-19
2. Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2.
Gene Rep. 2020 Apr 16;19:100682. doi: 10.1016/j.genrep.2020.100682. Epub ahead of
print. PMID: 32300673; PMCID: PMC7161481.

-- End of Report --

Page 2 / 2